Novartis Buys Tourmaline Bio: A Billion-Dollar Heart Deal
Update: 2025-09-09
Description
Novartis drops $1.4 billion to snag Tourmaline Bio, betting big on a potential heart disease breakthrough! The deal centers on pacibekitug, a promising anti-inflammatory drug targeting atherosclerotic cardiovascular disease. Tourmaline's stock skyrockets, while Novartis gains a potential blockbuster. Is this the future of heart disease treatment?
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
